# Sermonix Pharmaceuticals

- **Section**: news
- **Answer**: Sermonix Pharmaceuticals: 32 headlines on record, 0 headlines in the last 90 days. Its story counts 1 milestone.
- **As of**: 2026-11-17
- **Cite**: Sermonix Pharmaceuticals, News. Alion, Nov 17, 2026. https://alion.io/company/sermonixpharma/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 3792670
- **Name**: Sermonix Pharmaceuticals
- **Domain**: sermonixpharma.com
- **Url**: <https://alion.io/company/sermonixpharma>

## Figures

- Label: Headlines; Value: 32
- Label: In 90 days; Value: 0
- Label: Milestones; Value: 1

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 31
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 1

## News

- [Partners & Collaborations](https://sermonixpharma.com/partners-collaborations/) — Date: 2026-07-06; Kind: Blog
- [About Expanded Access](https://sermonixpharma.com/about-expanded-access/) — Date: 2026-07-06; Kind: Blog
- [Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"](https://sermonixpharma.com/athira-pharma-announces-name-change-to-leonabio-inc-with-new-ticker-lona/) — Date: 2026-01-09; Kind: Blog
- [Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million](https://sermonixpharma.com/athira-pharma-announces-exclusive-license-to-lasofoxifene-phase-3-development-program-for-metastatic-breast-cancer-candidate-and-a-financing-for-up-to-236-million/) — Date: 2025-12-19; Kind: Blog
- [The Elaine 3 Study](https://sermonixpharma.com/the-elaine-3-study/) — Date: 2025-12-18; Kind: Blog
- [The Elaine Study](https://sermonixpharma.com/the-elaine-study/) — Date: 2025-12-18; Kind: Blog
- [The Elaine 2 Study](https://sermonixpharma.com/the-elaine-2-study/) — Date: 2025-12-18; Kind: Blog
- [Posters & Presentations](https://sermonixpharma.com/medical-meetings/) — Date: 2025-04-28; Kind: Blog
- [Sermonix Pharmaceuticals' Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting](https://sermonixpharma.com/sermonix-pharmaceuticals-lasofoxifene-is-well-tolerated-demonstrates-promising-ki67-suppression-in-phase-2-i-spy-2-arm-evaluating-therapy-in-neoadjuvant-breast-cancer-setting/) — Date: 2025-04-11; Kind: Blog
- [Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics](https://sermonixpharma.com/sermonix-and-regor-announce-strategic-collaboration-to-optimize-regors-proprietary-rcard-platform-for-identification-of-novel-targets-and-therapeutics/) — Date: 2025-03-27; Kind: Blog
- [Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer](https://sermonixpharma.com/sermonix-announces-clinical-breast-cancer-publication-of-article-examining-effects-of-lasofoxifene-versus-fulvestrant-on-urogenital-symptoms-in-patients-with-esr1-mutated-er-her2-metastatic-breast-c/) — Date: 2025-01-29; Kind: Blog
- [Sermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference](https://sermonixpharma.com/sermonix-pharmaceuticals-to-host-oral-presentation-on-vaginal-and-sexual-health-at-rise-up-for-breast-cancer-conference/) — Date: 2024-10-21; Kind: Blog
- [Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting](https://sermonixpharma.com/sermonix-pharmaceuticals-completes-enrollment-of-phase-2-i-spy-2-arm-evaluating-lasofoxifene-in-neoadjuvant-breast-cancer-setting/) — Date: 2024-08-28; Kind: Blog
- [Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations](https://sermonixpharma.com/sermonix-pharmaceuticals-receives-u-s-patent-for-lasofoxifene-as-method-for-treating-aromatase-resistant-er-breast-cancer-in-the-absence-of-esr1-mutations/) — Date: 2024-07-18; Kind: Blog
- [Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene's Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-breast-cancer-research-publication-of-paper-examining-lasofoxifenes-preclinical-effects-on-aromatase-inhibitor-resistant-non-esr1-mutated-breast-cancer/) — Date: 2024-06-12; Kind: Blog
- [Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-chinese-approval-of-investigational-new-drug-application-for-lasofoxifene/) — Date: 2024-06-06; Kind: Blog
- [Sermonix Pharmaceuticals Announces 'Menopause' Journal Publication of Article on Oral Lasofoxifene's Effects on Vaginal Atrophy in Postmenopausal Women](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-menopause-journal-publication-of-article-on-oral-lasofoxifenes-effects-on-vaginal-atrophy-in-postmenopausal-women/) — Date: 2024-05-02; Kind: Blog
- [Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape](https://sermonixpharma.com/sermonix-to-host-kol-fireside-chat-on-advancements-in-the-metastatic-breast-cancer-treatment-landscape/) — Date: 2024-04-22; Kind: Blog
- [Sermonix Pharmaceuticals Announces MBC Alliance Membership, New 'Discover ELAINE' Website](https://sermonixpharma.com/sermonix-pharmaceuticals-announces-mbc-alliance-membership-new-discover-elaine-website/) — Date: 2024-02-14; Kind: Blog
- [Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene](https://sermonixpharma.com/henlius-and-sermonix-announce-strategic-collaboration-and-exclusive-license-agreements-for-novel-endocrine-therapy-lasofoxifene/) — Date: 2024-01-12; Kind: Blog
- [Who is Elaine?](https://sermonixpharma.com/who-is-elaine/) — Date: 2023-12-27; Kind: Blog
- [Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life](https://sermonixpharma.com/sermonix-pharmaceuticals-shares-resuits-of-third-survey-on-esr1-and-metastatic-breast-cancer-patient-quality-of-life/) — Date: 2023-12-14; Kind: Blog
- [A Bench-to-Bedside Story](https://dukecancerinstitute.org/blogs/bench-bedside-story) — Kind: News; Source: Duke Cancer Institute
- [Phase 2 Data Support Development of Lasofoxifene in ESR1-mutant, ER+HER2 Breast Cancer](https://onclive.com/view/phase-2-data-support-development-of-lasofoxifene-in-esr1-mutant-er-her2-breast-cancer) — Kind: News; Source: onclive.com
- [Future Directions of Lasofoxifene Research in Breast Cancer](https://targetedonc.com/view/future-directions-of-lasofoxifene-research-in-breast-cancer) — Kind: News; Source: targetedonc.com
- [Emerging ESR1-Targeted Therapy Added to Abemaciclib to Treat Metastatic ER+HER2 Breast Cancer](https://targetedonc.com/view/emerging-esr1-targeted-therapy-added-to-abemaciclib-to-treat-metastatic-er-her2-breast-cancer) — Kind: News; Source: targetedonc.com
- [ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+HER2- Breast Cancer](https://targetedonc.com/view/elaine-3-study-of-lasofoxifene-initiates-for-esr1-mutated-er-her2--breast-cancer) — Kind: News; Source: targetedonc.com
- [ELAINE-1 Trial Examines Lasofoxifene in ESR1+, ER+HER2- Breast Cancer](https://targetedonc.com/view/elaine-1-trial-examines-lasofoxifene-in-esr1-er-her2--breast-cancer) — Kind: News; Source: targetedonc.com
- [Durable CR With Lasofoxifene in ESR1+, ER+HER2- Metastatic Breast Cancer](https://targetedonc.com/view/durable-cr-with-lasofoxifene-in-esr1-er-her2--metastatic-breast-cancer) — Kind: News; Source: targetedonc.com
- [Dr. Damodaran on the ELAINE-2 Trial of LasofoxifeneAbemaciclib in ESR1-Mutated, ER+HER2- Breast Cancer](https://onclive.com/view/dr-damodaran-on-the-elaine-2-trial-of-lasofoxifene-abemaciclib-in-esr1-mutated-er-her2--breast-cancer) — Kind: News; Source: onclive.com
- [Episode #10 How to Beat Cancer by Lessons My Patients Taught Me](https://creators.spotify.com/pod/profile/elliot-davidson/episodes/Episode-10-How-to-Beat-Cancer-e17tld4) — Kind: Podcast; Source: Spotify for Creators

## Story

- **Founded**

---
[Page](https://alion.io/company/sermonixpharma/news) · [JSON](https://alion.io/company/sermonixpharma/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
